James Marcum, MD
Cardiovascular Disease · Overland Park, KSNPI 1942257886
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.0% of the total across 169 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by Abbott at 34.4% of the total. Reporting peaked in 2023 at $1,361 and has fallen 75.8% since, to $329 in 2025.
Across 169 payments — averaging $25.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- Boston Scientific$719
- Amgen$317
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$309
- Irhythm Technologies, Inc.$246
- Biotronik Inc.$182
- plus $1K from 20 others
Across 34 payments — averaging $756.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$26K
What the payments were for
- Food & beverage$4,10197%
- Education$1283%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 45 | $1,453 |
| Boston Scientific | 24 | $719 |
| Amgen | 18 | $317 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 19 | $309 |
| Irhythm Technologies, Inc. | 11 | $246 |
| Biotronik Inc. | 2 | $182 |
| Impulse Dynamics (USA) Inc. | 2 | $180 |
| Pfizer | 9 | $144 |
| Medtronic | 3 | $101 |
| Boehringer Ingelheim | 6 | $87 |
| Novo Nordisk | 5 | $86 |
| Philips North America LLC | 4 | $62 |
| Novartis | 3 | $44 |
| Lemaitre Vascular, Inc. | 2 | $44 |
| Teleflex LLC | 2 | $33 |
| E.r. Squibb & Sons, L.L.C. | 2 | $31 |
| Recor Medical Inc | 1 | $29 |
| Sanofi-aventis U.S. LLC | 2 | $28 |
| Esperion Therapeutics, Inc. | 2 | $27 |
| Kestra Medical Technology Services, Inc. | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| UCB, Inc. | 1 | $17 |
| AstraZeneca | 1 | $14 |
| Aegerion Pharmaceuticals, Inc. | 1 | $14 |
| Abiomed | 1 | $12 |
| Cvrx, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIMIZER$325
- AMVIA EDGE$148
- CardioMEMS HF System$128
- AVEIR$125
- AMPLATZER AMULET$105
- CARDIOMEMS$103
How this compares
$4,229 in reported general payments places this provider in the 65th percentile of 175 cardiovascular disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 148 | $163,646 |
| Repatha SureclickEvolocumab | 78 | $69,861 |
| EntrestoSacubitril/Valsartan | 73 | $58,228 |
| JardianceEmpagliflozin | 45 | $56,249 |
| XareltoRivaroxaban | 46 | $43,813 |
| FarxigaDapagliflozin Propanediol | 15 | $11,633 |
| Rosuvastatin Calcium | 271 | $2,935 |
| Metoprolol Succinate | 197 | $2,369 |
| Atorvastatin Calcium | 206 | $2,166 |
| Ranolazine ErRanolazine | 15 | $2,029 |
| Losartan Potassium | 229 | $1,664 |
| Nebivolol Hcl | 25 | $1,304 |
| Ezetimibe | 79 | $1,272 |
| Diltiazem 24hr Er (La)Diltiazem Hcl | 20 | $984 |
| Flecainide Acetate | 21 | $952 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $144 | $163,646148 claims |
| NovartisEntresto | $44 | $58,22873 claims |
| Boehringer IngelheimJardiance | $87 | $56,24945 claims |
| AstraZenecaFarxiga | $14 | $11,63315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 175 cardiovascular disease providers in Kansas.
Other cardiovascular disease in Overland Park
- Vasvi SinghOverland Park$405K
- Rachel SoslandOverland Park$33K
- Ahmed ElballatOverland Park$22K
- Paul NagerOverland Park$10K
- Ronnie SmallingOverland Park$9K
- van JonesOverland Park$7K
- Alan SchneiderOverland Park$6K
- Theodore PopeOverland Park$5K
- Stephen BloomOverland Park$5K
- Bassem ChehabWichita$482K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.